Results 31 to 40 of about 11,732 (171)

Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon‐Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Carbon‐ion radiotherapy (CIRT) provides superior dose distribution and higher biological effectiveness than conventional X‐ray radiotherapy and has emerged as a promising component of multidisciplinary treatment for advanced pancreatic ductal adenocarcinoma (PDAC).
Kenichiro Araki, Norio Kubo, Yuhei Miyasaka, Hayato Ikota, Ryo Muranushi, Mariko Tsukagoshi, Takamichi Igarashi, Masahiko Okamoto, Tatsuya Ohno, Ken Shirabe   +9 more
wiley   +1 more source

Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients

International Journal of Hyperthermia, 2019
Background: FOLFIRINOX chemotherapy displays significant survival improvements in patients with pancreatic cancer. However, toxicities have hampered enthusiasm for the use of FOLFIRINOX in full dose.
Meng He, Jinghua Sun, Danyi Zhao, Hongmei He, Bing Wang, Lingling Xu, Yu Shang, Shanling Ren, Yang Zhang, Tao Wu   +9 more
doaj   +1 more source

Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long‐Term Survival

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy.
Ryosuke Fukushima, Kenichiro Araki, Ryo Muranushi, Kouki Hoshino, Kei Hagiwara, Shunsuke Kawai, Mariko Tsukagoshi, Takamichi Igarashi, Norio Kubo, Ken Shirabe   +9 more
wiley   +1 more source

Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters

, 2019
International audienceFOLFIRINOX regimen is commonly used in colorectal and more recently pancreatic cancer. However, FOLFIRINOX induces significant and dose-limiting toxic effects leading to empirical dose reduction and sometimes treatment ...
Gattacceca, Florence, Deyme, Laure, Barbolosi, Dominique   +2 more
core   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

The efficacy of prophylactic GCSF for FOLFIRINOX.

, 2015
274 Background: Granulocyte Colony-Stimulating Factors (GCSF) is used as supportive care in cancer management when patients (pts) receive chemotherapy with high risk of febrile neutropenia (FN).
Shin Kuwakado, Hitoshi Nishitani, Tetsuji Terazawa, Masahiro Goto, Fukutaro Shimamoto, Kazuhide Higuchi, Ken Asaishi, Miyamoto Takahiro, Takayuki Kii   +8 more
core   +1 more source

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

BMC Cancer, 2019
Background Locally advanced or metastatic adenocarcinoma of the pancreas remains - despite the implementation of new chemotherapy protocols - a disease with short overall survival (OS).
Ursula M. Vogl, Haleh Andalibi, Alexander Klaus, Laurenz Vormittag, Wolfgang Schima, Bettina Heinrich, Alice Kafka, Thomas Winkler, Leopold Öhler   +8 more
doaj   +1 more source

Initial chemotherapy option for pancreatic ductal adenocarcinoma in patients with adequate performance status

Journal of Pancreatology, 2023
Pancreatic ductal adenocarcinoma (PDAC) is a highly progressive lethal malignancy, with chemotherapy being the primary treatment modality. This article provides a review of the initial chemotherapy options for PDAC patients with adequate performance ...
Jiazhang Xing, Yuping Ge, Xiaolei Gong, Yuan Liu, Yuejuan Cheng   +4 more
doaj   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. [PDF]

PLoS ONE, 2017
Hohla et al. suggested that female gender could positively predict response to FOLFIRINOX in patients with advanced pancreatic cancer. In this study, we explored the response to the FOLFIRINOX regimen by gender within the trial PRODIGE4/ACCORD 11.Data ...
Aurélien Lambert, Marta Jarlier, Sophie Gourgou Bourgade, Thierry Conroy   +3 more
doaj   +1 more source